Effect of the human SOD1-G93A gene on the Nrf2/ARE signaling pathway in NSC-34 cells

Molecular Medicine Reports

Volumn 9, Issue 6, 2014, Pages 2453-2458

  Wang, Fumin ^a,b   Lu, Yucheng ^b   Qi, Faying ^b   Su, Quanping ^b   Wang, Long ^b   You, Cuiping ^b   Che, Fengyuan ^b   Yu, Jixu ^b  

^a WEIFANG MEDICAL UNIVERSITY   (China)

^b LINYI PEOPLE'S HOSPITAL   (China)

Author keywords

Amyotrophic lateral sclerosis; Neurodegenerative disease; Nrf2 ARE pathway; NSC 34 cells; Oxidative stress; Phase II enzymes

Indexed keywords

HEME OXYGENASE 1; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR NRF2; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; MOUSE; NEURITE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOD1 G93A GENE; CELL LINE; DRUG DETOXIFICATION; EPISTASIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIPID PEROXIDATION; METABOLISM;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT RESPONSE ELEMENTS; CELL LINE; EPISTASIS, GENETIC; GENE EXPRESSION REGULATION; HUMANS; LIPID PEROXIDATION; METABOLIC DETOXICATION, PHASE II; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE;

EID: 84899675320     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2087     Document Type: Article

References (25)

1. Avossa D, Grandolfo M, Mazzarol F, et al: Early signs of motoneuron vulnerability in a disease model system: characterization of transverse slice cultures of spinal cord isolated from embryonic ALS mice. Neuroscience 138: 1179-1194, 2006. (Pubitemid 43363536)
2. Mitchell JD, Callagher P, Gardham J, et al: Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) - a 20-year review: can we do better? Amyotroph Lateral Scler 11: 537-541, 2010.
3. Kiernan MC, Vucic S, Cheah BC, et al: Amyotrophic lateral sclerosis. Lancet 377: 942-955, 2011.
4. Zinman L and Cudkowicz M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurology 10: 481-490, 2011.
5. Barber SC and Shaw PJ: Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radical Biol Med 48: 629-641, 2010.
6. Petri S, Körner S and Kiaei M: Nrf2/ARE signaling pathway: key mediator in oxidative stress and potential therapeutic target in ALS. Neurol Res Int 2012: 878030, 2012.
7. Valdmanis PN, Daoud H, Dion PA and Rouleau GA: Recent advances in the genetics of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep 9: 198-205, 2009.
8. Howland DS, Liu J, She Y, et al: Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA 99: 1604-1609, 2002. (Pubitemid 34136539)
9. Gurney ME, Pu H, Chiu AY, et al: Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264: 1772-1775, 1994. (Pubitemid 24227760)
10. Yu X and Kensler T: Nrf2 as a target for cancer chemoprevention. Mutat Res 591: 93-102, 2005. (Pubitemid 41654841)
11. Taguchi K, Motohashi H and Yamamoto M: Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16: 123-140, 2011.
12. Vargas MR and Johnson JA: The Nrf2-ARE cytoprotective pathway in astrocytes. Expert Rev Mol Med 11: e17, 2009.
13. Hybertson BM, Gao B, Bose SK and McCord JM: Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Aspects Med 32: 234-246, 2011.
14. Mariani E, Polidori MC, Cherubini A and Mecocci P: Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci 827: 65-75, 2005. (Pubitemid 41551598)
15. Shibata N, Nagai R, Uchida K, et al: Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 917: 97-104, 2001. (Pubitemid 32972133)
16. Sarlette A, Krampfl K, Grothe C, et al: Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 67: 1055-1062, 2008.
17. Pehar M, Vargas MR, Robinson KM, et al: Mitochondrial superoxide production and nuclear factor erythroid 2-related factor 2 activation in p75 neurotrophin receptor-induced motor neuron apoptosis. J Neurosci 27: 7777-7785, 2007. (Pubitemid 47093805)
18. Neymotin A, Calingasan NY, Wille E, et al: Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med 51: 88-96, 2011.
19. Malhotra D, Portales-Casamar E, Singh A, et al: Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 38: 5718-5734, 2010.
20. Poss KD and Tonegawa S: Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci USA 94: 10925-10930, 1997. (Pubitemid 27430837)
21. Siegel D, Gustafson DL, Dehn DL, et al: NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 65: 1238-1247, 2004. (Pubitemid 38543494)
22. Slocum SL and Kensler TW: Nrf2: control of sensitivity to carcinogens. Arch Toxicol 85: 273-284, 2011.
23. Vargas MR, Burton NC, Kutzke J, et al: Absence of Nrf2 or its selective overexpression in neurons and muscle does not affect survival in ALS-linked mutant hSOD1 mouse models. PLoS One 8: e56625, 2013.
24. Sun MM, Bu H, Li B, et al: Neuroprotective potential of phase II enzyme inducer diallyl trisulfide. Neurol Res 31: 23-27, 2009.
25. Stack C, Ho D, Wille E, et al: Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med 49: 147-158, 2010.